malonyl-CoA decarboxylase
آخر تحديث 26 يوليو 2023
يتوافق مع الإرشادات التحريرية
- تنزيلتنزيل
- مشاركة
- Language
- نقاش
- Ask Patient
- نسخة صوتية
- أضف إلى المصادر المفضلة على جوجل
ال MLYCD gene provides instructions for making an enzyme called malonyl-CoA decarboxylase. This enzyme helps regulate the formation and breakdown of a group of fats called fatty acids. Many tissues, including heart (cardiac) muscle, use fatty acids as a major source of energy. The body also uses fatty acids to build cell membranes, produce hormones, and carry out many other important processes.
اختيارات الفيديو لـ Genesمكتبة الفيديو
Normal function
ال MLYCD gene provides instructions for making an enzyme called malonyl-CoA decarboxylase. This enzyme helps regulate the formation and breakdown of a group of fats called fatty acids. Many tissues, including heart (cardiac) muscle, use fatty acids as a major source of energy. The body also uses fatty acids to build cell membranes, produce hormones, and carry out many other important processes.
Malonyl-CoA decarboxylase is responsible for the chemical reaction that converts a molecule called malonyl-CoA to a molecule called acetyl-CoA. This reaction is an important step in the breakdown of fatty acids. Acetyl-CoA is then used to make new fatty acids and can also be used to produce energy.
Malonyl-CoA decarboxylase is most active in cardiac muscle and in muscles used for movement (skeletal muscles). It is also found in other organs and tissues, including the brain, small intestine, liver, kidney, and pancreas. This enzyme probably functions in several parts of the cell, including mitochondria, which are cells' energy-producing centers, and peroxisomes, which are small sacs that process fatty acids and other molecules. Malonyl-CoA decarboxylase also functions in the fluid that surrounds these cell structures (the cytoplasm).
Conditions referring to this gene or chromosome
Other names
DCMC_HUMAN
hMCD
malonyl coenzyme A decarboxylase
MCD
Related patient information and medicines

Patient information leaflet
مرض باركنسون
What is مرض باركنسون. مرض باركنسون هو a progressive neurological degeneration of certain cells (called dopaminergic cells) within a specific part of the brain (substantia nigra). The deficiency... Which medicines are used to treat Parkinson's disease. Guidelines recommend starting with a الدوبامين agonist, levodopa with a.

Patient information leaflet
تضيق الشريان الأبهر
تضيق الشريان الأبهر is a type of congenital heart disease where there is a narrowing in part of the aorta, the main artery that leaves the left side of the heart. Normal heart detail Cross-section diagram of a normal heart PatientPicksPlaceholder Heart - lung circulation heart - lung circulation What is coarctation of the aorta. In.

Medicine leaflet
أقراص برافاستاتين
حول pravastatin Type of medicine A lipid-regulating medicine commonly known as a الستاتين Used for Lowering cholesterol and other lipids in the blood (including after an organ transplant); to reduce the risk of heart and blood vessel disease Available as Tablets Lipids, or fats, are easily stored in your body and serve as a source of energy..

Medicine leaflet
أقراص وكبسولات فلوفاستاتين
Fluvastatin belongs to a group of medicines known as statins. It regulates the amount of cholesterol and other lipids made by your body, and helps to reduce the risk of heart and blood vessel disease. The narrowing reduces the blood flow through the artery and increases the risk of a number of heart and blood vessel diseases, such a... Fluvastatin.

Medicine leaflet
أقراص أتورفاستاتين
About atorvastatin Type of medicine A lipid-regulating medicine commonly known as a statin Used for Lowering cholesterol and other lipids; to reduce the risk of heart and blood vessel disease Also called (UK) Lipitor® Also called (USA) Lipitor®; Combination brand: Caduet® (atorvastatin with amlodipine Amlodipine tablets ) Available as Tablets and.

Medicine leaflet
Rosuvastatin
Rosuvastatin belongs to a group of medicines known as statins. It regulates ... About rosuvastatin Type of medicine A lipid-regulating medicine commonly known as a statin Used for Lowering cholesterol and other lipids in the blood; to reduce the risk of heart and blood vessel disease Also called Crestor® Available as Tablets and capsules Lipids,.
قراءة إضافية ومراجع
- malonyl-CoA decarboxylase; MedlinePlus, National Library of Medicine.
- Chapel-Crespo C, Gavrilov D, Sowa M, Myers J, Day-Salvatore DL, Lynn H, Regier D, Starin D, Steenari M, Schoonderwoerd K, Abdenur JE. Clinical, biochemical and molecular characteristics of malonyl-CoA decarboxylase deficiency and long-term follow-up of nine patients. Mol Genet Metab. 2019 Sep-Oct;128(1-2):113-121. doi: 10.1016/j.ymgme.2019.07.015. Epub 2019 Jul 29. No abstract available.
- Kasapkara CS, Civelek Urey B, Ceylan AC, Unal Uzun O, Cetin II. Malonyl coenzyme A decarboxylase deficiency with a novel mutation. Cardiol Young. 2021 Sep;31(9):1535-1537. doi: 10.1017/S104795112100113X. Epub 2021 Mar 22.
- Salomons GS, Jakobs C, Pope LL, Errami A, Potter M, Nowaczyk M, Olpin S, Manning N, Raiman JA, Slade T, Champion MP, Peck D, Gavrilov D, Hillman R, Hoganson GE, Donaldson K, Shield JP, Ketteridge D, Wasserstein M, Gibson KM. Clinical, enzymatic and molecular characterization of nine new patients with malonyl-coenzyme A decarboxylase deficiency. J Inherit Metab Dis. 2007 Feb;30(1):23-8. doi: 10.1007/s10545-006-0514-6. Epub 2006 Dec 20.
- Surendran S, Sacksteder KA, Gould SJ, Coldwell JG, Rady PL, Tyring SK, Matalon R. Malonyl CoA decarboxylase deficiency: C to T transition in intron 2 of the MCD gene. J Neurosci Res. 2001 Sep 15;65(6):591-4. doi: 10.1002/jnr.1189.
- Wightman PJ, Santer R, Ribes A, Dougherty F, McGill N, Thorburn DR, FitzPatrick DR. MLYCD mutation analysis: evidence for protein mistargeting as a cause of MLYCD deficiency. Hum Mutat. 2003 Oct;22(4):288-300. doi: 10.1002/humu.10264.
- Zhang JM, Hao LL, Qiu WJ, Zhang HW, Chen T, Ji WJ, Zhang Y, Liu F, Gu XF, Yang SH, Han LS. Clinical, biochemical and genetic characteristics and long-term follow-up of five patients with malonyl-CoA decarboxylase deficiency. Brain Dev. 2024 Oct;46(9):286-293. doi: 10.1016/j.braindev.2024.07.001. Epub 2024 Jul 27.
تاريخ المقال
المقال متاح أيضًا باللغة الإنجليزية, الألمانية, إسبانية, الفرنسية, إيطالي, البرتغالية, الهندية, العبرية, العربية ,، و السويدية.
26 يوليو 2023 | أحدث إصدار
1 Jan 2010 | نُشر في الأصل
شارك أفكارك أو تجاربك مع الآخرين في مجتمعات المرضى.
اشترك في النشرة الإخبارية للمرضى
جرعتك الأسبوعية من النصائح الصحية الواضحة والموثوقة - مكتوبة لمساعدتك على الشعور بالاطلاع والثقة والتحكم.
من خلال الاشتراك، فإنك تقبل سياسة الخصوصية. يمكنك إلغاء الاشتراك في أي وقت. نحن لا نبيع بياناتك أبدًا.

